<DOC>
	<DOCNO>NCT00021671</DOCNO>
	<brief_summary>The purpose study see antibiotic drug give treat infection uterus pregnancy reduce chance HIV pass HIV-positive mother baby . A link bacterial disease vagina , premature birth , infection uterus pregnancy , pass HIV mother baby find . Early treatment problem may reduce risk pass HIV HIV-positive mother baby . [ Note : As 02/21/03 , enrollment study halt preliminary data show study antibiotic effective prevent mother-to-child HIV transmission . ]</brief_summary>
	<brief_title>Antibiotics Reduce Chorioamnionitis-Related Perinatal HIV Transmission</brief_title>
	<detailed_description>Obstetric risk factor HIV maternal-child transmission ( MCT ) include preterm birth , prolonged rupture membrane , chorioamnionitis . Many preterm birth associate likely cause chorioamnionitis . The relationship bacterial vaginosis , preterm birth , histologic chorioamnionitis , perinatal transmission HIV consistently demonstrate . Perinatal HIV transmission common preterm infant , evidence subclinical chorioamnionitis substantial risk factor MCT . For study , primary hypothesis early appropriate treatment subclinical chorioamnionitis prior onset spontaneous preterm labor , and/or antibiotic treatment labor , prevent premature rupture membrane-associated-chorioamnionitis , reduce risk perinatal HIV transmission . [ Note : As 02/21/03 , enrollment study halt preliminary data show study antibiotic effective prevent mother-to-child HIV transmission . ] At 20 24 week , woman randomize receive antibiotic receive metronidazole erythromycin 7 day . Women randomize control group receive identically appear placebo . With onset contraction and/or premature rupture membrane , study participant initiate second oral course antibiotic consist metronidazole ampicillin placebo every 4 hour , continue delivery course complete . All HIV-infected woman neonate offer HIVNET 012 nevirapine ( NVP ) regimen . If mother accepts NVP baby , give 1 dose NVP take onset labor , baby receive 1 dose NVP 72 hour post-birth discharge , whichever occur early . If mother refuse NVP uninfected , receive match placebo 26- 30-week visit preserve participant confidentiality . This study take place Blantyre Lilongwe , Malawi , Lusaka , Zambia , Dar e Salaam , Tanzania .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Chorioamnionitis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Inclusion Criteria HIV positive . 20 24 week pregnant . Willing take plan antibiotic treatment . Planning deliver 1 study site . Willing come back followup visit 1 year baby bear . Exclusion Criteria Have take antibiotic , except syphilis gonorrhea , within last 2 week . Are allergic penicillin , ampicillin , erythromycin , metronidazole . Have major illness , diabetes , severe kidney heart disease , active tuberculosis , might affect pregnancy . Are major problem pregnancy , placenta previa , rupture membrane , multiple pregnancy . Have central nervous system disease , seizure . Are take anticoagulant drug .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ampicillin</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Erythromycin</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Chorioamnionitis</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>